Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?

What is it about?

Lipodystrophy syndromes are a group of rare diseases defined by total or partial absence of fat. An important role of fat tissue is to store excess energy. When there is not enough fat tissue to store excess lipids, the continuous consumption of energy (which is the reality in our world today) becomes a big problem. In this study, we report the impact of tirzepatide which is an approved weight loss drug. By reducing the incoming calories, we report that the metabolic problems can be controlled even when we cannot create new storage space in lipodystrophy. While our study is not a controlled study, it highlights that this treatment holds potential and should be tested further to provide hope for a population for whom treatment options are very limited.

Featured Image